Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
BPC-157 and anxiety: what the evidence says
Rodent studies suggest BPC-157 has anxiolytic effects. Human self-reports are mixed. No controlled human trial has measured anxiety as an outcome.
BPC-157 oral vs injectable for gut health
No human trial has compared oral BPC-157 tablets to reconstituted injectable for gut health. Here is what rodent data and the supply chain show.
BPC-157 personal reviews: what they show
Personal peptide reviews name doses and outcomes but lack controls and verified purity. Here is how to read them against actual BPC-157 data.
Is BPC-157 prohibited in sport? WADA rules
BPC-157 is banned under S0 of the WADA Prohibited List. Here is how the rule works, what USADA enforces, and what athletes need to know.
How BPC-157 works: a plain-English guide
BPC-157 appears to promote tissue repair in rodents through angiogenesis and nitric-oxide signalling. Here is what the preclinical data shows.
BPC-157 dosing: what the studies used
No validated human dose for BPC-157 exists. The 200 to 500 mcg range quoted online is an allometric extrapolation from rodent injury models, not clinical data.
What is BPC-157? A plain-English explainer
BPC-157 is a synthetic peptide from human gastric juice studied in rodents for tissue repair. No controlled human trial exists, and it is not approved anywhere.
ACP review: which obesity drugs pay off?
A new ACP systematic review rates tirzepatide high-value but flags poor study quality across all obesity drug cost models.
ACP: tirzepatide, semaglutide first-line
A living ACP guideline published 16 June 2026 places tirzepatide and semaglutide first among pharmacologic obesity treatments for US outpatient adults.
GLP-1 drugs and plastic surgery risks
A 2026 review examines wound risks, aspiration concerns and body-contouring challenges when aesthetic surgery patients use GLP-1 agonists.
Medicare's $50 GLP-1 bridge may never end
A temporary Medicare program offers GLP-1 weight-loss drugs for $50 a month from July 2026. It has already been extended once.
Low-dose semaglutide cuts weight in HARMONY
The HARMONY cohort from China reports 9.9% mean weight loss at 24 weeks on semaglutide 0.5 or 1.0 mg weekly, below the 2.4 mg obesity dose.